Lim JK, et al. - The safety and effectiveness of 12 or 24 weeks treatment with ledipasvir and sofosbuvir, with or without ribavirin were evaluated, in treatment-experienced patients with hepatitis C virus (HCV) genotype 1 infection and cirrhosis, during routine clinical practice. Treatment with ledipasvir and sofosbuvir (with or without ribavirin) was found to be effective and well tolerated by treatment-experienced patients with genotype 1 HCV infection and compensated cirrhosis. No significant differences were noted in the rate of sustained virologic response (SVR)12 among patients treated with ledipasvir and sofosbuvir for 12 or 24 weeks, with or without ribavirin. Patients with decompensated cirrhosis seemed to benefit from the addition of ribavirin or extension of ledipasvir and sofosbuvir treatment to 24 weeks.